Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Kos Pharmaceuticals, Inc (KOSP) -- Ignore unavailable to you. Want to Upgrade?

To: JerryR who wrote (39)	3/14/1998 8:30:00 PM
From: vera haller	Read Replies (1) \| Respond to of 118

This is the first time I have visited your site. I was trying to do some research on Kos for one of our investment group members. One of her clients is a rep for this company. I am confused about the prices you guys have been quoting. When I looked it up today it is only at around $8. Are we looking at the same company?

To: JerryR who wrote (39)	9/27/2000 12:44:12 PM
From: Bipin Prasad	Respond to of 118

CORRECTED - Kos, DuPont seek OK from FDA Tue Sep 26 14:36:00 EDT 2000 In the WILMINGTON, Del. item "Kos, DuPont seek OK from FDA on cholesterol drug," please read in first graph "for the cholesterol fighting drug developed by Kos and co-marketed by DuPont Pharmaceuticals," instead of "co-developed." In second graph, read "marketing deal" instead of "research pact," and delete "development" from first sentence of fourth graph. (Corrected to show DuPont/Kos co-marketing, not co-developing, drug.) A corrected version follows. WILMINGTON, Del., Sept 26 (Reuters) - DuPont Co.'s drug subsidiary and Kos Pharmaceuticals Inc. on Tuesday said they have submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for the cholesterol-fighting drug formerly known as Nicostatin, developed by Kos and co-marketed by DuPont Pharmaceuticals. The two companies, which in May signed a multimillion-dollar marketing deal, said they expect approval from the FDA by the end of 2001. Kos said it is developing a new brand name for the drug, which combines Kos' Niaspan and Lovastatin therapies. Upon regulatory approval, the two companies said they will jointly market the drug. Kos and DuPont also said they expect to apply for regulatory approval in Canada and Europe. The niacin/lovastatin therapy is currently in Phase IV trials. This summer DuPont Pharmaceuticals said it would provide up to $80 million in funding to Kos for the cholesterol management therapy, which in recent tests demonstrated the capacity to raise "good" cholesterol up to 40 percent and lower "bad" cholesterol by almost 50 percent, to help patients lower their risk for heart disease. Shares of Kos closed at $16 on the Nasdaq stock market on Monday, while shares of DuPont closed at $39-3/16 on the New York Stock Exchange.